'Our daughter's eye changed in matter of hours before diagnosis left us in tears'

The uncommon cancer strikes between 40 and 50 people annually, typically children under five, and has resulted in Ava losing ...
JCN Newswire

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...